Phase 3 Readout~month

Phase 3 Topline: China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safe

Indication
Metastatic Hormone Sensitive Prostate Cancer

Other upcoming events for CPHI

Phase 3 ReadoutPhase 3 Topline: Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safe — CPHI Phase 3 Readout | BioSniper